JP2023533111A5 - - Google Patents
Info
- Publication number
- JP2023533111A5 JP2023533111A5 JP2022568780A JP2022568780A JP2023533111A5 JP 2023533111 A5 JP2023533111 A5 JP 2023533111A5 JP 2022568780 A JP2022568780 A JP 2022568780A JP 2022568780 A JP2022568780 A JP 2022568780A JP 2023533111 A5 JP2023533111 A5 JP 2023533111A5
- Authority
- JP
- Japan
- Prior art keywords
- sting agonist
- inhibitor
- use according
- ctla4
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063025905P | 2020-05-15 | 2020-05-15 | |
| US63/025,905 | 2020-05-15 | ||
| US202063091874P | 2020-10-14 | 2020-10-14 | |
| US63/091,874 | 2020-10-14 | ||
| PCT/US2021/032800 WO2021232019A1 (en) | 2020-05-15 | 2021-05-17 | Sting agonist combination treatments with immune checkpoint inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533111A JP2023533111A (ja) | 2023-08-02 |
| JP2023533111A5 true JP2023533111A5 (cg-RX-API-DMAC10.html) | 2024-05-24 |
Family
ID=76306053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568780A Pending JP2023533111A (ja) | 2020-05-15 | 2021-05-17 | 免疫チェックポイント阻害剤とのstingアゴニスト併用治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210380695A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4149457A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023533111A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230011324A (cg-RX-API-DMAC10.html) |
| CN (1) | CN115803032A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021273508A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3178464A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL298148A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2022014110A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021232019A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114940679B (zh) * | 2022-05-23 | 2023-05-16 | 浙江大学医学院附属第四医院 | Sting激动剂前药化合物及其制备方法和应用 |
| WO2024064724A1 (en) * | 2022-09-21 | 2024-03-28 | The University Of North Carolina At Chapel Hill | Compositions and methods for treating cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2935257T3 (es) | 2013-03-15 | 2023-03-03 | Univ Chicago | Métodos y composiciones relacionadas con la actividad de las células T |
| JP2016524593A (ja) | 2013-04-29 | 2016-08-18 | メモリアル スローン−ケタリング キャンサー センター | セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法 |
| EP2996472B1 (en) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| CN103908468B (zh) | 2014-04-21 | 2017-02-08 | 上海捌加壹医药科技有限公司 | 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 |
| DK3233882T3 (da) | 2014-12-16 | 2020-01-27 | Kayla Therapeutics | Fluorinerede cykliske dinukleotider til cytokininduktion |
| EP4122492A1 (en) * | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| CN108137641B (zh) | 2015-08-13 | 2022-04-01 | 默沙东公司 | 作为sting激动剂的环状双核苷酸化合物 |
| US20170158772A1 (en) | 2015-12-07 | 2017-06-08 | Opi Vi - Ip Holdco Llc | Compositions of antibody construct - agonist conjugates and methods of use thereof |
| DE212016000029U1 (de) | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
| IL280430B2 (en) * | 2016-03-18 | 2023-11-01 | Univ Texas | Cyclic dinucleotide compounds and methods of use |
| RU2019122598A (ru) | 2016-12-20 | 2021-01-22 | Мерк Шарп И Доум Корп. | Циклические динуклеотидные агонисты sting для лечения рака |
| WO2018118664A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
| CA3049791A1 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| EP3675859A4 (en) | 2017-08-31 | 2021-06-30 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES |
| EP3755331B1 (en) | 2018-02-21 | 2026-01-28 | The Scripps Research Institute | Agonists of stimulator of interferon genes (sting) for use in the treatment of cancer |
| JP2023500045A (ja) * | 2019-10-14 | 2023-01-04 | イミューンセンサー セラピューティクス、インコーポレイテッド | Stingアゴニストを用いたがんを処置する方法 |
-
2021
- 2021-05-17 EP EP21730772.7A patent/EP4149457A1/en active Pending
- 2021-05-17 KR KR1020227042332A patent/KR20230011324A/ko active Pending
- 2021-05-17 MX MX2022014110A patent/MX2022014110A/es unknown
- 2021-05-17 WO PCT/US2021/032800 patent/WO2021232019A1/en not_active Ceased
- 2021-05-17 AU AU2021273508A patent/AU2021273508A1/en not_active Abandoned
- 2021-05-17 CA CA3178464A patent/CA3178464A1/en active Pending
- 2021-05-17 US US17/322,827 patent/US20210380695A1/en not_active Abandoned
- 2021-05-17 IL IL298148A patent/IL298148A/en unknown
- 2021-05-17 JP JP2022568780A patent/JP2023533111A/ja active Pending
- 2021-05-17 CN CN202180046447.0A patent/CN115803032A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Theiss et al. | Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis | |
| Aglietta et al. | A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer | |
| Wang et al. | Treatment of chronic subdural hematoma with atorvastatin combined with low-dose dexamethasone: phase II randomized proof-of-concept clinical trial | |
| Goedegebuure et al. | Combining radiotherapy with anti-angiogenic therapy and immunotherapy; a therapeutic triad for cancer? | |
| Yamaguchi et al. | Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab | |
| McDermott et al. | A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon α-2B in patients with metastatic melanoma | |
| Theiss et al. | Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction | |
| RU2011104955A (ru) | Композиции антител | |
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| CA2993179A1 (en) | Combination of immunomodulatory agent with pd-1-or pd-l1 checkpoint inhibitors in the treatment of cancer | |
| Flowers et al. | Efficacy of pharmacokinetics-directed busulfan, cyclophosphamide, and etoposide conditioning and autologous stem cell transplantation for lymphoma: comparison of a multicenter phase II study and CIBMTR outcomes | |
| JP2019508433A5 (cg-RX-API-DMAC10.html) | ||
| JP2019218359A (ja) | Gd2陽性がんを処置するための製剤および方法 | |
| Numico et al. | Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence | |
| JP2023539625A5 (cg-RX-API-DMAC10.html) | ||
| JP2019533715A5 (cg-RX-API-DMAC10.html) | ||
| CA3160502A1 (en) | Formulations of anti-cd38 antibodies for subcutaneous administration | |
| Puri et al. | Effects of different doses of intraumbilical oxytocin on the third stage of labor | |
| Song et al. | Glutamine protects mice from acute graft-versus-host disease (aGVHD) | |
| Schwartz et al. | Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)–paclitaxel or docetaxel adjuvant chemotherapy in breast cancer | |
| Lee et al. | Pharmacological treatments for basal cell carcinoma | |
| Zhao et al. | Emerging immunological strategies: recent advances and future directions | |
| IL320024A (en) | Perk inhibitor hc-5404 in combination with anti-pd-1 antibody and/or an antiangiogenetic agent for use in the treatment of cancer | |
| Pabón-Cartagena et al. | Eosinophilic fasciitis in association with nivolumab: The importance of eosinophilia | |
| Petitdemange et al. | Immune checkpoint inhibitors-induced systemic capillary leak syndrome: a report of two cases |